SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~June~~July 2913, 2020

SIBANNAC, INC.

(Exact name of registrant as specified in its charter)

Nevada	333-122009	33-0903494
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)

9535 E Doubletree Ranch Road, Ste 120

Scottsdale, AZ 85258

Tel. (480) 407-6445

(Address and Telephone Number of Principal Executive Offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b 2 of this chapter). Emerging growth company ☐

If any emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

SIBANNAC, INC.

Form 8-K

Current Report

~~ITEM~~Item 18.01. ~~ENTRY~~Other ~~INTO A MATERIAL DEFINITIVE AGREEMENT~~Events.

The Company has obtained a registration number from the Food and Drug Administration (FDA) for the operation of a food facility. The Company will be ~~entering~~ ~~into~~manufacturing ana ~~Asset~~full ~~Purchase~~line ~~Agreement~~of ~~with~~Cannabidiol (CBD) ~~NOHO~~products, ~~Inc.~~including ingestibles, as well as a ~~Wyoming~~number ~~corporation~~of ~~(OTC~~formulations ~~Pink:~~with ~~DRNK)~~B17 and apricot seeds, for ~~the~~ sale ofunder ~~NOHO’s~~brands owned ~~intellectual~~by ~~property~~the Company.

~~The~~In ~~Boards~~order ofto ~~Directors of~~continue ~~both~~compliance ~~firms~~with ~~are~~all ~~finalizing~~cGMP ~~the~~(current ~~assets~~Good Manufacturing toPractices) bemanufacturing ~~conveyed~~protocols ~~and~~as ~~the~~contained ~~terms~~in of the ~~sale.~~federal ~~Notably~~regulations, ~~Sibannac~~the ~~intends~~Company tohas ~~use~~retained ~~the~~a ~~NOHO brand~~consultant ~~and~~who ~~its~~has ~~viable~~created ~~social~~all ~~media~~the ~~platforms~~necessary processes and ~~followers~~procedures in order to ~~launch~~safely ~~new~~manufacture ~~formulations~~products ~~and~~for ~~delivery~~the ~~methods~~consumer ofmarket. ~~hangover~~The Company ~~products~~is in ~~combination with~~the ~~CBD~~process ~~(Cannabidiol).~~of ~~The~~negotiating ~~products~~the ~~will~~manufacture beof ~~manufactured~~several ~~and~~custom ~~distributed~~formulated ~~from~~CBD ~~Sibannac’s~~products, ~~new~~including ~~facility~~rare ingredients not typically found in ~~Scottsdale,~~the ~~Arizona~~current marketplace.

The ~~proposed~~Company’s ~~transactions~~CEO, ~~will~~David beMersky, ~~structured~~has inexchanged the ~~following~~Forty-Three ~~steps.~~Million ~~First,~~Eight ~~Sibannac~~Hundred ~~will~~Seventy-Two ~~create~~Thousand aEight ~~privately~~Hundred ~~held~~Six ~~specific purpose acquisition company to~~(43,872,806) beshares ~~funded by newly registered Sibannac securities, consisting~~ of ~~units of~~ common stock, ~~and~~issued ~~warrants.~~in ~~The~~conjunction ~~companies~~with ~~will~~the ~~then~~initial ~~enter into~~acquisition anin ~~asset~~2017, ~~purchase~~for ~~agreement~~shares of ~~using~~ the ~~newly~~recently ~~issued~~created ~~securities~~Preferred asClass ~~consideration~~B ~~to NOHO~~stock. ~~NOHO~~The ~~will~~issued ~~then~~and ~~enter~~outstanding ~~into~~common ashares ~~share exchange~~remain orat ~~buyback agreement~~16,127,104, ~~effecting the exchange~~ of ~~Sibannac~~which ~~securities~~only ~~for~~1,015,000 are ~~NOHO~~free-trading ~~stock~~and ~~held~~on ~~by NOHO shareholders~~deposit.

~~The~~Forward-Looking transaction as contemplated will result in the exchange of free trading NOHO shares for free trading Sibannac shares. The exchange rate and share price is being negotiated at this time. The transaction is subject to accounting and audit review as well as regulatory approval.Statements

~~The~~This ~~parties~~Current ~~intend~~Report toon ~~complete~~Form ~~the~~8-K ~~transaction~~includes instatements that may constitute “forward-looking” statements, usually containing the ~~Fall~~words of“believe”, “estimate”, ~~2020~~“project”, “anticipate”, “expect” or similar expressions. ~~NOHO~~These ~~shareholders~~statements are ~~will~~made bepursuant ~~advised~~to ~~within~~the ~~sixty~~safe ~~(60)~~harbor ~~days~~provisions of the ~~closing~~Private Securities Litigation Reform Act of ~~the~~1995. Forward-looking statements ~~effective~~inherently ~~date~~involve ~~for~~risks ~~the~~and ~~shareholders~~uncertainties ofthat ~~record~~could cause actual results to ~~participate~~differ inmaterially from the ~~exchange~~forward-looking statements.

ITEM 8.01 OTHER EVENTS

The following shall constitute an update on the previously announced entry into a material agreement. The target acquisition is for a controlling interest in Richardson Nutritional Center (RNC), a California based Apricot seed marketing and sales firm founded by John Richardson, Jr., son of renowned physician, John A. Richardson, M.D. See, Laetrile Case Histories: The Richardson Cancer Clinic Experience, July 2005. The main compound found in Apricot seed kernels is B17, which is found in citrus fruits as well. Laetrile is concentrated B17. Until such time as clinical trials and other medical support involving B17 establish its benefits, the Company will not market products with any medicinal or drug claims.

Mr. Richardson, Jr. has been in the business of processing, formulating and selling Apricot seed-based products for more than 20 years. Apricot seeds are primarily grown in northern California, which produces approximately 85% of the entire domestic U.S. output. Through the proposed acquisition, Sibannac would assume the offtake contracts for the entirety of the annual harvests. Sibannac can treat the raw seeds with CBD, offering a natural food product as a hybrid as it is currently marketed or as a stand-alone product. While there is potential synergy with CBD in formulations such as capsules, the strength of this acquisition results from Sibannac’s ability to grow its footprint in the natural health space, independent of CBD and the uncertainty of the future regulatory framework surrounding it. Foremost, however, is that Sibannac will control the U.S. Apricot seed market and intends to use this to the company’s advantage to set it apart in the evolving competitive landscape. Mr. Richardson is well known throughout the country in the alternative health space for his long history and work in the Apricot kernel marketplace. He was interviewed by BuzzFeed News as a recognized authority on B17 and is a frequent lecturer on the topic throughout the United States.

In anticipation of the closing of the acquisition, the RNC personnel have relocated from California to Arizona, and all operations, including sales and distribution are being conducted out of Sibannac’s facility in Scottsdale.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SIBANNAC, INC.
Date: June 29, 2020	By: /s/ David Mersky
Date: July 13, 2020	By: /s/ David Mersky
		David Mersky
		Chief Executive Officer

Filing Compare · Sibannac, Inc.